Position in TGTX
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$2,989,833
+$1,648,383 QoQ
Shares Held
90,001
+100.0% QoQ
Ownership
0.059%
of shares outstanding
% of Portfolio
2.35%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2021
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TGTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Knott David M Jr holds $72,324,865 across 34 Biotechnology names. TGTX ranks #10 (4.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SNDX |
Syndax Pharmaceuticals Inc
|
422,000 | $9,857,920 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
90,000 | $6,683,400 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
63,000 | $6,640,200 | |
| 4 | IOVA |
Iovance Biotherapeutics, Inc.
|
1,600,000 | $5,616,000 | |
| 5 | TVTX |
Travere Therapeutics, Inc.
|
140,633 | $4,178,206 | |
| 6 | COGT |
Cogent Biosciences, Inc.
|
104,000 | $4,002,960 | |
| 7 | VRDN |
Viridian Therapeutics, Inc.\DE
|
181,000 | $3,540,360 | |
| 8 | AGIO |
Agios Pharmaceuticals, Inc.
|
93,058 | $3,148,152 |
All Filings in TGTX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,989,833 | 90,001 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $1,341,450 | 45,000 | Shares | Defined | 2026-02-12 | |
| 2021-12-31 | $638,248 | 33,592 | Shares | Defined | 2022-02-11 | |
| No filing history on record for this holder in this stock. | ||||||